Rodriguez-Massó, Sergio R 
; Erickson, Michelle A; Banks, William A; Ulrich, Henning ; Martins, Antonio Henrique
Source: Frontiers in Neuroscience. Unidade: IQ
Subjects: HOMEOSTASE, SISTEMA NERVOSO CENTRAL, BRADICININA, BARREIRA HEMATO-ENCEFÁLICA, PEPTÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RODRIGUEZ-MASSÓ, Sergio R et al. The bradykinin B2 receptor agonist (NG291) causes rapid onset of transient blood–brain barrier disruption without evidence of early brain injury. Frontiers in Neuroscience, v. 15, p. 1-17, 2021Tradução . . Disponível em: https://doi.org/10.3389/fnins.2021.791709. Acesso em: 16 jun. 2024.APA
Rodriguez-Massó, S. R., Erickson, M. A., Banks, W. A., Ulrich, H., & Martins, A. H. (2021). The bradykinin B2 receptor agonist (NG291) causes rapid onset of transient blood–brain barrier disruption without evidence of early brain injury. Frontiers in Neuroscience, 15, 1-17. doi:10.3389/fnins.2021.791709NLM
Rodriguez-Massó SR, Erickson MA, Banks WA, Ulrich H, Martins AH. The bradykinin B2 receptor agonist (NG291) causes rapid onset of transient blood–brain barrier disruption without evidence of early brain injury [Internet]. Frontiers in Neuroscience. 2021 ; 15 1-17.[citado 2024 jun. 16 ] Available from: https://doi.org/10.3389/fnins.2021.791709Vancouver
Rodriguez-Massó SR, Erickson MA, Banks WA, Ulrich H, Martins AH. The bradykinin B2 receptor agonist (NG291) causes rapid onset of transient blood–brain barrier disruption without evidence of early brain injury [Internet]. Frontiers in Neuroscience. 2021 ; 15 1-17.[citado 2024 jun. 16 ] Available from: https://doi.org/10.3389/fnins.2021.791709
